ImmuCell Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $88.2M
- Price
- $10.06
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.30%
- Volume
- 11.1K
About
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Quick stats
Shares outstanding9.0M
Computed float6.0M
Float / shares66.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000811641
Websitehttps://immucell.com
AI Summary
AI-generated1/14
majorbullishearnings
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
ImmuCell reported Q2 revenue of $7.2 million, up 11.5% year-over-year, with net income rising to $1.8 million or $0.20 per diluted share.
Cash and cash equivalents increased significantly to $8.9 million, aided by a one-time $2 million settlement payment from a former contract manufacturer, though gross margins contracted to 34% due to lower volumes and manufacturing scrap.
The company authorized a two-phase capacity expansion program totaling approximately $8 million to triple production capacity for its First Defense product line over the next 18 months.
Red flags
- Gross margin declined to 33.9% from 43.7% year-over-year due to manufacturing headwinds and quality issues
- Net income included a non-recurring $2 million legal settlement payment